Kala Pharmaceuticals, Inc. Insider Trading
KALA
No open-market buying or selling by insiders.
The last open-market buy by an executive or director was in Oct 2020.
Get an email when KALA's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Oct 22, 2025 – Oct 23, 2025 | Mary Reumuth Chief Financial Officer | SoldNo plan 2 parts | 33,197 | $0.83 average | 28K | 53% | Form 4 |
| Oct 23, 2025 | Mark T Iwicki Director | SoldNo plan | 154,894 | $0.81 | 125K | 60% | Form 4 |
| Oct 22, 2025 | Darius Kharabi Chief Business Officer | SoldNo plan | 20,806 | $0.83 | 17K | 33% | Form 4 |
| Oct 22, 2025 | Todd Bazemore Director | SoldNo plan | 47,768 | $0.83 | 40K | 57% | Form 4 |
| Oct 22, 2025 | Romulus K Brazzell See Remarks | SoldNo plan | 46,748 | $0.83 | 39K | 57% | Form 4 |
| Sep 30, 2025 – Oct 1, 2025 | Julian Baker Other | SoldNo plan 4 parts | 730,408 | $1.45 average | $1.06M | 63% | Form 4 |
| Jun 24, 2025 | Darius Kharabi Chief Business Officer | Sold10b5-1 plan | 4,511 | $4.01 | 18K | 6.7% | Form 4 |
| Jun 24, 2025 | Mary Reumuth Chief Financial Officer | Sold10b5-1 plan | 3,631 | $4.01 | 15K | 5.5% | Form 4 |
| Jun 24, 2025 | Todd Bazemore See Remarks | Sold10b5-1 plan | 4,058 | $4.01 | 16K | 4.6% | Form 4 |
| Jun 24, 2025 | Romulus K Brazzell See Remarks | Sold10b5-1 plan | 5,251 | $4.01 | 21K | 6.0% | Form 4 |
| Jun 24, 2025 | Mark T Iwicki Director | Sold10b5-1 plan | 13,227 | $4.01 | 53K | 4.9% | Form 4 |
| Jun 3, 2025 | Mark T Iwicki Director | Sold10b5-1 plan | 10,866 | $3.74 | 41K | 3.9% | Form 4 |
| Jun 3, 2025 | Darius Kharabi Chief Business Officer | Sold10b5-1 plan | 730 | $3.74 | 3K | 1.1% | Form 4 |
| Jun 3, 2025 | Mary Reumuth Chief Financial Officer | Sold10b5-1 plan | 2,850 | $3.74 | 11K | 4.2% | Form 4 |
| Jun 3, 2025 | Todd Bazemore See Remarks | Sold10b5-1 plan | 3,390 | $3.74 | 13K | 3.7% | Form 4 |
| Jun 3, 2025 | Romulus K Brazzell See Remarks | Sold10b5-1 plan | 3,687 | $3.74 | 14K | 4.0% | Form 4 |
| Jan 6, 2025 | Darius Kharabi Chief Business Officer | Sold10b5-1 plan | 2,021 | $7.63 | 15K | 2.9% | Form 4 |
| Jan 6, 2025 | Todd Bazemore See Remarks | Sold10b5-1 plan | 1,993 | $7.63 | 15K | 100% | Form 4 |
| Jan 6, 2025 | Romulus K Brazzell See Remarks | Sold10b5-1 plan | 2,446 | $7.63 | 19K | 2.6% | Form 4 |
| Jan 6, 2025 | Mark T Iwicki Chief Executive Officer | Sold10b5-1 plan | 5,779 | $7.63 | 44K | 2.0% | Form 4 |
| Jan 6, 2025 | Mary Reumuth Chief Financial Officer | Sold10b5-1 plan | 1,706 | $7.63 | 13K | 2.4% | Form 4 |
| Dec 30, 2024 | Felix Baker Large holder | Bought 2 parts | 310,559 | $6.44 average | 197K | 40% | Form 4 |
- Oct 22, 2025 – Oct 23, 2025No planMary ReumuthChief Financial Officer · sold 33,197 at avg $0.8328K53% of stake
- Oct 23, 2025No planMark T IwickiDirector · sold 154,894 at $0.81125K60% of stake
- Oct 22, 2025No planDarius KharabiChief Business Officer · sold 20,806 at $0.8317K33% of stake
- Oct 22, 2025No planTodd BazemoreDirector · sold 47,768 at $0.8340K57% of stake
- Oct 22, 2025No planRomulus K BrazzellSee Remarks · sold 46,748 at $0.8339K57% of stake
- Sep 30, 2025 – Oct 1, 2025No planJulian BakerOther · sold 730,408 at avg $1.45$1.06M63% of stake
- Jun 24, 202510b5-1 planDarius KharabiChief Business Officer · sold 4,511 at $4.0118K6.7% of stake
- Jun 24, 202510b5-1 planMary ReumuthChief Financial Officer · sold 3,631 at $4.0115K5.5% of stake
- Jun 24, 202510b5-1 planTodd BazemoreSee Remarks · sold 4,058 at $4.0116K4.6% of stake
- Jun 24, 202510b5-1 planRomulus K BrazzellSee Remarks · sold 5,251 at $4.0121K6.0% of stake
- Jun 24, 202510b5-1 planMark T IwickiDirector · sold 13,227 at $4.0153K4.9% of stake
- Jun 3, 202510b5-1 planMark T IwickiDirector · sold 10,866 at $3.7441K3.9% of stake
- Jun 3, 202510b5-1 planDarius KharabiChief Business Officer · sold 730 at $3.743K1.1% of stake
- Jun 3, 202510b5-1 planMary ReumuthChief Financial Officer · sold 2,850 at $3.7411K4.2% of stake
- Jun 3, 202510b5-1 planTodd BazemoreSee Remarks · sold 3,390 at $3.7413K3.7% of stake
- Jun 3, 202510b5-1 planRomulus K BrazzellSee Remarks · sold 3,687 at $3.7414K4.0% of stake
- Jan 6, 202510b5-1 planDarius KharabiChief Business Officer · sold 2,021 at $7.6315K2.9% of stake
- Jan 6, 202510b5-1 planTodd BazemoreSee Remarks · sold 1,993 at $7.6315K100% of stake
- Jan 6, 202510b5-1 planRomulus K BrazzellSee Remarks · sold 2,446 at $7.6319K2.6% of stake
- Jan 6, 202510b5-1 planMark T IwickiChief Executive Officer · sold 5,779 at $7.6344K2.0% of stake
- Jan 6, 202510b5-1 planMary ReumuthChief Financial Officer · sold 1,706 at $7.6313K2.4% of stake
- Dec 30, 2024Felix BakerLarge holder · bought 310,559 at avg $6.44197K40% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with KALA
Spot a number that looks wrong? Check it in KALA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing KALA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.